UroGen Pharma Ltd.
Hedge Funds Holdings
Last updated:
UroGen Pharma Ltd.‘s stocks are currently a part of 80 hedge funds’ portfolios, which represents 63.63% of the total amount of its stocks outstanding. This makes up a total of 14.21M shares of UroGen Pharma Ltd.. Compared to the previous quarter, the number fell by -3.44% or -505.88K shares fewer. As for the holding position changes, 25% (20) of current hedge fund investors increased the number of shares held, 26.25% (21) of current holders sold a part of the shares held, and 10% (8) closed the holdings completely. 15 hedge funds are new holders of UroGen Pharma Ltd. stock in Q1 2022, it is 18.75% of total holders.
Hedge funds holding UroGen Pharma Ltd. (Q2 2017 – Q1 2022)
| Q2 2017 | 21 |
|---|---|
| Q3 2017 | 32 |
| Q4 2017 | 41 |
| Q1 2018 | 43 |
| Q2 2018 | 60 |
| Q3 2018 | 71 |
| Q4 2018 | 63 |
| Q1 2019 | 73 |
| Q2 2019 | 84 |
| Q3 2019 | 81 |
| Q4 2019 | 84 |
| Q1 2020 | 77 |
| Q2 2020 | 82 |
| Q3 2020 | 77 |
| Q4 2020 | 79 |
| Q1 2021 | 87 |
| Q2 2021 | 81 |
| Q3 2021 | 88 |
| Q4 2021 | 74 |
| Q1 2022 | 80 |
Hedge funds changes in UroGen Pharma Ltd. positions (Q2 2017 – Q1 2022)
| Q2 2017 | 21 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|
| Q3 2017 | 14 | 5 | 6 | 3 | 4 |
| Q4 2017 | 14 | 13 | 8 | 5 | 1 |
| Q1 2018 | 10 | 21 | 7 | 8 | -3 |
| Q2 2018 | 23 | 21 | 12 | 6 | -2 |
| Q3 2018 | 19 | 23 | 18 | 8 | 3 |
| Q4 2018 | 10 | 25 | 18 | 16 | -6 |
| Q1 2019 | 20 | 38 | 9 | 10 | -4 |
| Q2 2019 | 25 | 27 | 19 | 13 | 0 |
| Q3 2019 | 13 | 41 | 13 | 14 | 0 |
| Q4 2019 | 10 | 40 | 23 | 7 | 4 |
| Q1 2020 | 4 | 30 | 31 | 11 | 1 |
| Q2 2020 | 13 | 39 | 16 | 8 | 6 |
| Q3 2020 | 2 | 27 | 31 | 7 | 10 |
| Q4 2020 | 11 | 24 | 26 | 10 | 8 |
| Q1 2021 | 11 | 22 | 35 | 2 | 17 |
| Q2 2021 | 7 | 24 | 28 | 13 | 9 |
| Q3 2021 | 12 | 25 | 24 | 5 | 22 |
| Q4 2021 | 7 | 20 | 22 | 20 | 5 |
| Q1 2022 | 15 | 20 | 21 | 8 | 16 |
Hedge funds changes in UroGen Pharma Ltd. stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 0 | 0 |
|---|---|---|
| Q3 2017 | 0 | 0 |
| Q4 2017 | 0 | 0 |
| Q1 2018 | 0 | 0 |
| Q2 2018 | 0 | 0 |
| Q3 2018 | 0 | 359,000 |
| Q4 2018 | 348,000 | 0 |
| Q1 2019 | 1,382,000 | 447,000 |
| Q2 2019 | 1,441,000 | 553,000 |
| Q3 2019 | 1,634,000 | 2,264,000 |
| Q4 2019 | 8,035,000 | 8,546,000 |
| Q1 2020 | 4,893,000 | 3,552,000 |
| Q2 2020 | 5,931,000 | 7,477,000 |
| Q3 2020 | 3,716,000 | 4,963,000 |
| Q4 2020 | 2,054,000 | 4,967,000 |
| Q1 2021 | 2,166,000 | 1,654,000 |
| Q2 2021 | 1,337,000 | 1,314,000 |
| Q3 2021 | 1,460,000 | 1,438,000 |
| Q4 2021 | 5,000 | 4,000 |
| Q1 2022 | 0 | 4,000 |